Ad Hoc Announcement Pursuant to Art. 53 LR
Geneva, Switzerland, March 10, 2022 - Addex Therapeutics (SIX:ADXN and Nasdaq:ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today reported financial results for the full-year ended December 31, 2021 and provided a corporate update.
Read more at globenewswire.com